In the meantime, ibrutinib can also reduce the drug resistance of tumor cells to paclitaxel by inhibiting the outflow function of the ATP-binding cassette subfamily B member 1 (ABC B1/P-glycoprotein) and subfamily C member 10 (ABCC 10/MRP 7) (54). Here, ABCB1 is linked to neoplasm.